Fedha

Hisa unazofuatilia
GRF:BME
Grifols SA Class A
€ 9.64
+1.15%
(+0.11) Siku 1
5 Okt, 15:01:12 GMT +2  ·   EUR
Alama zote
AlamaBeiTofautiTofauti ya asilimia
Inatayarisha maarifa maarufu ya GRF...
Fungua
€ 9.55
Juu
€ 9.67
Chini
€ 9.55
Mtaji wa soko
5.84B
Wastani wa kiasi cha mauzo
1.14M
Kiasi cha mauzo ya hisa
elfu 429.83
Gawio
2.41%
Mgawo wa faida wa kila robo mwaka
€ 0.06
Tarehe ya kutojumuisha gawio
30 Jun 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
14.50
Juu kwa wiki 52
€ 12.87
Chini kwa wiki 52
€ 8.43
EPS
€ 0.67
Hisa za wawekezaji
426.13M
Idadi ya wafanyakazi
elfu 25
Fungua
€ 9.55
Juu
€ 9.67
Chini
€ 9.55
Mtaji wa soko
5.84B
Wastani wa kiasi cha mauzo
1.14M
Kiasi cha mauzo ya hisa
elfu 429.83
Gawio
2.41%
Mgawo wa faida wa kila robo mwaka
€ 0.06
Tarehe ya kutojumuisha gawio
30 Jun 2026
Uwiano wa bei ya hisa na mapato kwa kila hisa
14.50
Juu kwa wiki 52
€ 12.87
Chini kwa wiki 52
€ 8.43
EPS
€ 0.67
Hisa za wawekezaji
426.13M
Idadi ya wafanyakazi
elfu 25
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
Wasifu
Grifols, S.A. is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Catalonia, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over 30. Principally a producer of blood plasma–based products and other biopharmaceuticals, the company also operates in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, as well as clinical diagnostic technologies. Furthermore, it provides biological supplies for life-science research, clinical trials and the manufacturing of pharmaceutical and diagnostic products. It has a portfolio on four therapeutic areas: immunology, infectious diseases, pulmonology and critical care. Wikipedia
Kuhusu Grifols SA Class A
Afisa Mkuu Mtendaji (CEO)Nacho Abia
Wafanyakazielfu 25
Lilianzishwa18 Nov 1940
Makao makuu-
Sekta-
Ripoti ya mwisho
28 Jul 2026
Kipindi cha Kifedha
Robo2 2026
Mapato kwa kila hisa dhidi ya makadirio (EUR)
- / -
Mapato dhidi ya makadirio (EUR)
1.87B / 1.89B
Mkutano pepe wa kujadili mapato ya robo ya Robo ya 2 ya mwaka wa fedha wa 2026
Inasubiri mkutano pepe wa kujadili mapato
Kwa muhtasari
Maarifa kutoka kwenye ripoti na habari za hivi punde
Ripoti za awaliThamani zote katika EUR
Loading Previous Earnings...
Mapato
Mapato halisi
Thamani zote katika EUR
Sep 2025
Des 2025
Mac 2026
Jun 2026
Mapato
1.87B
1.98B
1.70B
1.87B
Gharama ya bidhaa zilizouzwa
1.11B
1.28B
1.06B
1.19B
Gharama ya mapato
1.11B
1.28B
1.06B
1.19B
Gharama za utafiti na maendeleo
97.01M
90.82M
90.00M
86.00M
Jumla ya gharama za utafiti na maendeleo
-
-
-
-
Gharama za uuzaji, za jumla na za usimamizi
273.76M
262.86M
269.00M
301.00M
Gharama ya uendeshaji
370.34M
353.11M
359.00M
387.00M
Jumla ya gharama za uendeshaji
1.48B
1.63B
1.42B
1.58B
Mapato ya uendeshaji
381.18M
347.38M
280.00M
298.00M
Mapato mengine yasiyo ya uendeshaji
-
-33.00M
-
-13.00M
EBT ikijumuisha vipengee visivyo vya kawaida
198.13M
111.10M
112.00M
247.00M
EBT bila kujumuisha vipengee visivyo vya kawaida
227.20M
183.10M
143.00M
216.00M
Gharama ya kodi ya mapato
54.71M
-14.68M
24.00M
64.00M
Kiwango cha kodi kinachotumika
27.61%
-13.21%
21.43%
25.91%
Gharama nyingine za uendeshaji
elfu -430.00
elfu -570.00
-
-
Mapato halisi
126.96M
98.25M
73.00M
154.00M
Kiwango cha faida halisi
6.81%
4.96%
4.29%
8.22%
Mapato kwa kila hisa
-
-
-
-
Mapato ya riba na uwekezaji
-
36.00M
-
120.00M
Gharama ya riba
-156.07M
-107.99M
-139.00M
-179.00M
Jumla ya gharama halisi za riba
-156.07M
-71.99M
-139.00M
-59.00M
Gharama za kushuka kwa thamani na za kulipa deni
-
-
-
-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni
484.03M
422.88M
384.00M
364.00M
Faida au hasara kutokana na uuzaji wa vipengee
-
2.00M
-
-6.00M
Maudhui yaliyotayarishwa kwa AI yanaweza kuwa na makosa. Pata maelezo zaidi
Programu za Google